Abstracts Archive - Page 121 of 2607 - ACR Meeting Abstracts

Abstract Number: 1568 • ACR Convergence 2025
A Novel Endothelial Cell Profiling Assay to Identify Systemic Sclerosis Patient Characteristics at the Endothelial Cell Level
Eva Hoekstra¹, Rudmer Postma¹, Nils Steinz², Wieke van Oostveen¹, Roel Bijkerk¹, Vincent van Duinen², Rachel Knevel², Tom Huizinga², Anton jan van Zonneveld¹, Jeska de Vries-Bouwstra² and Cynthia Fehres¹, ¹Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Vasculopathy, a hallmark clinical feature in systemic sclerosis (SSc), is a consequence of endothelial cell (EC) damage and dysfunction and might precede tissue fibrosis.…
Abstract Number: 1618 • ACR Convergence 2025
Use of JAK inhibitors in patients with refractory Takayasu arteritis: A worldwide retrospective study
Fatma Alibaz-Oner¹, İbrahim yahya Çakır², Alessandro Tomelleri³, Aysegul Avcu⁴, Kaitlin Quinn⁵, Durga Prasanna Misra⁶, Matthew Koster⁷, Peter Grayson⁸, Alojzija Hocevar⁹, Kenan Aksu¹⁰, Duygu Kerim¹¹, Ertugrul Cağrı Bolek¹², Elena Baldissera¹³, Corrado Campochiaro¹⁴, Lorenzo Dagna¹⁵, Sema Kaymaz-Tahra¹⁶ and Haner Direskeneli⁴, ¹MARMARA UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF INTERNAL MEDICINE, DIVISION OF RHEUMATOLOGY, Istanbul, Turkey, ²Gazi University, Ankara, ³IRCCS San Raffaele Hospital, Milan, Italy, Milano, Italy, ⁴Marmara University, Istanbul, Turkey, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁶Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, Lucknow, Uttar Pradesh, India, ⁷Mayo Clinic, Rochester, MN, ⁸National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD, ⁹University Medical Center Ljubljana, LJUBLJANA, Slovenia, ¹⁰Ege Uni. Tip Fak., Istanbul, Turkey, ¹¹Ege University, Izmir, ¹²Gazi University, Rheumatology, Ankara, ¹³IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Diseases, Milan, Italy, Milan, ¹⁴IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ¹⁵Ospedale San Raffaele, Milano, Italy, ¹⁶Bahcesehir University Faculty of Medicine Department of Internal Medicine Division of Rheumatology, Istanbul, Turkey
Background/Purpose: Glucocorticoids(GCs) are the mainstay of treatment in Takayasu arteritis (TAK). Conventional DMARDs(cDMARDs) and biologic DMARDS(bDMARDs) are often used as steroid sparing agents in TAK.…
Abstract Number: 1599 • ACR Convergence 2025
Cyclophosphamide versus Rituximab in the treatment of Anca-associated Vasculitis: Adverse events and Relapses
Fabricio Benavides Villanueva¹, Diana Prieto-Peña², Vanesa Calvo-Río³, Monica Renuncio-García⁴, Adrian Martin-Gutierrez⁵, Amparo Sanchez-Lopez⁶, Claudia Poo-fernandez⁷, maria Rodríguez-Vidriales⁸ and Ricardo Blanco³, ¹Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Immunopathology Group,Santander, Spain, Santander, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain, ³Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ⁴Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain, ⁵Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Renedo de Piélagos, Spain, ⁶Division of Dermatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain, ⁷Division of Pneumology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain, ⁸Division of Nephrology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis include Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), and Eosinophilic Granulomatosis with Polyangiitis (EGPA). EGPA presents a different pathogenic,…
Abstract Number: 1563 • ACR Convergence 2025
RESET-SSc: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), A Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Systemic Sclerosis
Dinesh Khanna¹, Monalisa Ghosh¹, Ankoor Shah², Sonali Bracken³, george georges⁴, Carrie Richardson⁵, Pei-Suen Tsou¹, Charles Ross⁶, Carleigh Zahn¹, Courtney Little⁷, Carl diCasoli⁷, Mikaela Raymond⁷, Adreeja GuhaRay⁷, Jenell Volkov⁷, Daniel Nunez⁷, Thomas Furmanak⁷, Jason Stadanlick⁷, Larissa Ishikawa⁷, Zachary Vorndran⁷, Alexandra Ellis⁷, Jazmean Williams⁷, Steve Flanagan⁷, Quynh Lam⁸, Domenick Braccia⁸, Fatemeh Hadi-Nezhad⁸, Raj Tummala⁸, Samik Basu⁷ and David Chang⁹, ¹University of Michigan, Ann Arbor, MI, ²Duke University, Durham, NC, ³Duke University Medical Center, Durham, NC, USA, Apex, NC, ⁴Northwestern Medicine, Evanston, IL, ⁵Northwestern University, Chicago, IL, ⁶University of Michigan, Ann Arbor, ⁷Cabaletta Bio, Philadelphia, PA, ⁸Cabaletta Bio, Philadelphia, ⁹Cabaletta Bio, Bryn Mawr, PA
Background/Purpose: The treatment goals for systemic sclerosis (SSc) are to control disease activity, limit progression of organ damage and decrease long-term morbidity and mortality. Therapies…
Abstract Number: 1509 • ACR Convergence 2025
Outcome of Newly Diagnosed SLE with Serositis and Its Clinical Features in Daily Clinical Practice: A Single Center Study
Shuzo Sato, Kaito Moriuchi, So Yamamoto, Hiroki Nibu, Takahito Sakamoto, Shotaro Ogawa, Kenji Saito, Yuya Sumichika, Shuhei Yoshida, Haruki Matsumoto, Jumpei Temmoku and Tomoyuki Asano, Fukushima Medical University, Fukushima, Fukushima, Japan
Background/Purpose: Past reports have shown that serositis is a risk factor for organ damage in patients with SLE. However, the distinct clinical features of newly…
Abstract Number: 1615 • ACR Convergence 2025
Prevalence of Clinical and Laboratory Manifestations of Patients with Deficiency of Adenosine Deaminase 2 (DADA2): A Systematic Review and Meta-Analysis
Athanasios Vassilopoulos¹, Stephanos Vassilopoulos¹, Anushri Nimbvikar¹, Eleftherios Mylonakis² and Anthony M. Reginato³, ¹Division of Internal Medicine, Warren Alpert Medical School of Brown University, Rhode Island Hospital, Providence, Rhode Island, Providence, ²Department of Medicine, Houston Methodist Hospital, Houston, ³Brown University, Providence, RI
Background/Purpose: Deficiency of adenosine deaminase 2 (DADA2) is a rare autosomal recessive autoinflammatory disorder first identified in 2014. Four major disease phenotypes have been described:…
Abstract Number: 1642 • ACR Convergence 2025
The Impact of Secukinumab on Bone Density in Patients with Ankylosing Spondylitis: A 1-Year Retrospective Study
yifan cui¹, qingyan li², xiaoyue zhang³, qiuhao zheng⁴, tianshu chu⁵ and lemei an³, ¹Henan Provincial People's Hospital, zhengzhou, Henan, China (People's Republic), ²Henan Provincial People's Hospital, zhengzhou, China (People's Republic), ³Henan Provincial People's Hospital, zhengzhou, ⁴Henan Provincial People's Hospital, Zheng Zhou, China (People's Republic), ⁵Henan Provincial People's Hospital, Zheng Zhou Shi, Henan, China (People's Republic)
Background/Purpose: Ankylosing spondylitis (AS) is characterized by dysregulated bone remodeling, encompassing both osteolysis and heterotopic new bone formation. The differential effects of interleukin-17 (IL-17) inhibition…
Abstract Number: 1616 • ACR Convergence 2025
Short-Course Prednisone and Methotrexate in Polymyalgia Rheumatica: A Potential Therapeutic Approach
Edoardo Conticini¹, Silvia Grazzini¹, Raffaele Truscelli², Paolo Falsetti³, Luca Cantarini⁴ and Bruno Frediani⁴, ¹Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Italy, Siena, Italy, ²University of Siena, Siena, Italy, ³Siena University Hospital, Siena, Italy, ⁴Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University Hospital of Siena, Siena, Italy, Siena, Italy
Background/Purpose: Despite being considered an easy-to-diagnose and easy-to-treat condition, the optimal treatment of PMR is far from being fully elucidated. Three recently published trials have…
Abstract Number: 1512 • ACR Convergence 2025
Anti-U1-RNP Antibody Positivity is Associated with Elevated Interferon Score in SLE Irrespective of Disease Activity: A Transcriptome Analysis in Japanese Patients
Takemichi Matsui¹, Yumi Tsuchida², Takahiro Itamiya², Mineto Ota², Toshihiko Komai², Haruka Tsuchiya², Hirofumi Shoda², Tomohisa Okamura² and Keishi Fujio², ¹Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York, NY, ²Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Background/Purpose: With the introduction of anifrolumab to clinical practice, there is a growing interest in identifying factors associated with IFN activity in patients with SLE.…
Abstract Number: 1519 • ACR Convergence 2025
Post-hoc Analysis of Sustained Response Over Time in Systemic Lupus Erythematosus Patients Treated with Cenerimod in CARE (Phase 2 B) Study
Anca Askanase¹, Bruno Flamion², Ouali Berkani² and Cecile Dubois², ¹Columbia University Medical Center, New York, NY, ²Viatris Innovation, Allschwil, Switzerland
Background/Purpose: Cenerimod is a highly selective S1P1 receptor modulator which is undergoing trials for potential therapeutic benefits in autoimmune disease, including Systemic Lupus Erythematous (SLE).…
Abstract Number: 1612 • ACR Convergence 2025
Window of opportunity with tocilizumab therapy in giant cell arteritis. Multicenter study of 471 patients of clinical practice
Adrian Martin-Gutierrez¹, Javier Loricera², Diana Prieto-Peña³, Vicente Aldasoro Cáceres⁴, Olga Maiz⁵, Eugenio de Miguel⁶, Eva Galíndez Agirregoikoa⁷, Ivan Ferraz Amaro⁸, Santos Castañeda⁹ and Ricardo Blanco¹⁰, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Renedo de Piélagos, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain, ⁴Hospital Universitario de Navarra, Pamplona, Spain, ⁵Hospital Universitario de Donosti, Donostia, Spain, ⁶Hospital Universitario La Paz, Madrid, Spain, ⁷BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ⁸Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁹Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ¹⁰Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Tocilizumab (TCZ) is the only biological drug currently approved for the treatment of giant cell arteritis (GCA), regardless of GCA duration. The “window of…
Abstract Number: 1554 • ACR Convergence 2025
Demographic, Clinical, and Mortality Trends in Scleroderma Patients with Gastric Antral Vascular Ectasia (GAVE): A National Inpatient Analysis
Akanksha Sharma¹, Veera Durga Vaishnavi Kurra² and Neev Mehta³, ¹UPMC Mercy hospital, Pittsburgh, PA, Pittsburgh, PA, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Lahey Hospital and Medical Center, Burlington, MA
Background/Purpose: Gastric antral vascular ectasia (GAVE), commonly known as “watermelon stomach,” is a rare but potentially severe gastrointestinal manifestation in systemic sclerosis (SSc). Despite its…
Abstract Number: 1648 • ACR Convergence 2025
Predicting Worse Disease Activity, QOL, and Progression to Advanced Therapies at 12 and 24 months in Early RA: Results from the Canadian Early Arthritis Cohort (CATCH)
Susan J. Bartlett¹, Marie-France Valois², Clifton Bingham³, Janet Pope⁴, Hugues Allard-Chamard⁵, Louis Bessette⁶, Gilles Boire⁷, Carol Hitchon⁸, Glen Hazlewood⁹, Bindee Kuriya¹⁰, Carter Thorne¹¹ and Vivian Bykerk¹², ¹McGill University, Beaconsfield, QC, Canada, ²McGill University, Pointe-Claire, QC, Canada, ³Johns Hopkins University, Baltimore, MD, ⁴University of Western Ontario, London, ON, Canada, ⁵Université de Sherbrooke, Sherbrooke, Canada, ⁶Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ⁷Retired, Sherbrooke, QC, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹University of Calgary, Calgary, AB, Canada, ¹⁰University of Toronto - Toronto, Toronto, ON, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Hospital for Special Surgery, New York, NY
Background/Purpose: Pain, fatigue, and emotional distress are common in new RA patients. It is unclear whether co-occurring symptoms predict worse outcomes and progression to advanced therapies…
Abstract Number: 1625 • ACR Convergence 2025
Factor VIII as a Potential Biomarker of Disease Activity in Relapsing Polychondritis
Ashika Ajitumar¹, Eric Robbins², Yusuf Mastoor² and Marcela ferrada³, ¹University of Maryland, baltimore, MD, ²University of Maryland, baltimore, ³University of Maryland, Bethesda, MD
Background/Purpose: Relapsing polychondritis (RP) is a rare autoimmune disease marked by episodic inflammation of cartilaginous tissues. A major challenge in its clinical management is the…
Abstract Number: 1529 • ACR Convergence 2025
Updated Phase 1 Trial Data Assessing the Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BMS-986353 (CC-97540), a CD19-directed Chimeric Antigen Receptor T Cell Therapy Using a Next-Generation Process for Severe, Refractory SLE
Georg Schett¹, David Simon², Margrit Wiesendanger³, Anca Askanase⁴, Vikas Majithia⁵, Neil Kramer⁶, Jacques Morel⁷, Philip J. Mease⁸, Ellen De Langhe⁹, Amit Saxena¹⁰, dominique Farge¹¹, Alain Lescoat¹², Alisha Desai¹³, Griff McTume¹⁴, Whitney Handy¹⁴, Sharmila Das¹³, Jerill Thorpe¹⁴, Alexis Melton¹⁴, Ashley Koegel¹⁴ and Emily Littlejohn¹⁵, ¹Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ²Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Germany, ³Icahn School of Medicine at Mount Sinai, New York, NY, ⁴Columbia University Medical Center, New York, NY, ⁵Mayo Clinic Hospital, Jacksonville, FL, ⁶Overlook Medical Center; Atlantic Medical Group, Atlantic Health System, Summit, NJ, ⁷CHU and University of Montpellier, Montpellier, France, ⁸Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ⁹University Hospitals Leuven, Leuven, Belgium, ¹⁰Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, ¹¹Hôpital Saint-Louis, Paris, France, ¹²CHU Rennes University Hospital, Rennes, France, ¹³Bristol Myers Squibb, Princeton, NJ, ¹⁴Bristol Myers Squibb, Princeton, ¹⁵Cleveland Clinic, Cleveland, OH
Background/Purpose: BMS-986353 (CC-97540; CD19 NEX-T) is a CD19-directed chimeric antigen receptor (CAR) T cell therapy that expresses the same CAR as lisocabtagene maraleucel (liso-cel); it…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].